[go: up one dir, main page]

AR079696A1 - Composiciones farmacéuticas que comprenden bimatoprost, brimonidina y timolol y su uso para preparar un medicamento util para reducir la presion intraocular - Google Patents

Composiciones farmacéuticas que comprenden bimatoprost, brimonidina y timolol y su uso para preparar un medicamento util para reducir la presion intraocular

Info

Publication number
AR079696A1
AR079696A1 ARP100104881A ARP100104881A AR079696A1 AR 079696 A1 AR079696 A1 AR 079696A1 AR P100104881 A ARP100104881 A AR P100104881A AR P100104881 A ARP100104881 A AR P100104881A AR 079696 A1 AR079696 A1 AR 079696A1
Authority
AR
Argentina
Prior art keywords
brimonidine
timolol
intraocular pressure
prepare
pharmaceutical compositions
Prior art date
Application number
ARP100104881A
Other languages
English (en)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43743470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR079696(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR079696A1 publication Critical patent/AR079696A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones para la reduccion de la presion intraocular (IOP) de un ojo, que comprende, una combinacion de agentes de reduccion de la IOP bimatoprost, brimonidina, y timolol. Además se revelan los métodos para reducir la IOP en el ojo de un sujeto.
ARP100104881A 2009-12-22 2010-12-22 Composiciones farmacéuticas que comprenden bimatoprost, brimonidina y timolol y su uso para preparar un medicamento util para reducir la presion intraocular AR079696A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28893609P 2009-12-22 2009-12-22
US36174910P 2010-07-06 2010-07-06

Publications (1)

Publication Number Publication Date
AR079696A1 true AR079696A1 (es) 2012-02-15

Family

ID=43743470

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104881A AR079696A1 (es) 2009-12-22 2010-12-22 Composiciones farmacéuticas que comprenden bimatoprost, brimonidina y timolol y su uso para preparar un medicamento util para reducir la presion intraocular

Country Status (15)

Country Link
US (1) US20130116254A1 (es)
CN (1) CN102695498A (es)
AR (1) AR079696A1 (es)
BR (1) BR112012017319A2 (es)
CL (1) CL2012001736A1 (es)
CO (1) CO6592061A2 (es)
CR (1) CR20120360A (es)
EC (1) ECSP12012033A (es)
GT (1) GT201200213A (es)
IN (1) IN2012DN06416A (es)
MX (1) MX2012007397A (es)
NI (1) NI201200112A (es)
PE (2) PE20121468A1 (es)
TW (1) TW201143773A (es)
WO (1) WO2011087790A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
EP3434257A1 (en) 2010-07-29 2019-01-30 Allergan, Inc. Preservative free brimonidine and timolol solutions
EP2841104A1 (en) * 2012-04-24 2015-03-04 Allergan, Inc. Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use
EP4420726A3 (en) * 2015-03-19 2024-11-13 Allergan, Inc. Fixed dose combination of bromonidine and timolol
EP3810082A1 (en) * 2018-06-19 2021-04-28 Cella Therapeutics, LLC Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
US12042502B2 (en) * 2022-03-21 2024-07-23 Somerset Therapeutics, Llc Enhanced penetration ophthalmic compositions of bimatoprost and timolol

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US4994274A (en) 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5028624A (en) 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution

Also Published As

Publication number Publication date
TW201143773A (en) 2011-12-16
IN2012DN06416A (es) 2015-10-09
MX2012007397A (es) 2012-08-15
NI201200112A (es) 2013-04-09
PE20121468A1 (es) 2012-10-28
CN102695498A (zh) 2012-09-26
CO6592061A2 (es) 2013-01-02
GT201200213A (es) 2014-08-29
PE20160904A1 (es) 2016-09-16
BR112012017319A2 (pt) 2016-04-19
CR20120360A (es) 2012-07-30
ECSP12012033A (es) 2012-10-30
US20130116254A1 (en) 2013-05-09
CL2012001736A1 (es) 2012-10-12
WO2011087790A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
MX368377B (es) Combinacion de brimonidina y timolol para uso oftalmico, topico.
AR062046A1 (es) Soluciones oftalmicas
AR079696A1 (es) Composiciones farmacéuticas que comprenden bimatoprost, brimonidina y timolol y su uso para preparar un medicamento util para reducir la presion intraocular
MX2019014539A (es) Agentes multibioticos y metodos para utilizarlos.
CL2009000985A1 (es) Composicion oftalmica que comprende entre 0,16 y 0,19% p/v de un galactomanano, alrededor de 0,7% p/v de un borato, cis-diol y menos de 5 ppm de concentracion de cationes divalentes; y su uso para lubricar el ojo.
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
MX2009010289A (es) Composiciones para administracion nasal.
CR8858A (es) Derivados de sulfamato y sulfamida para el tratamiento de epilepsia y trastornos relacionados
NZ603345A (en) Stabilized ophthalmic galactomannan formulations
MX2015009785A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2019001877A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
CL2011002675A1 (es) Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.
BR112014017780A8 (pt) Compostos de sulfona tricíclicos e métodos para fazer e usar os mesmos
CL2004000899A1 (es) Composicion farmaceutica que contiene la sal sodica de telmisartan y un agente diuretico y procedimiento de preparacion.
ES2613698T3 (es) Combinación, kit y método de reducción de la presión intraocular
CL2012002038A1 (es) Metodo para reducir la presion intraocular que comprende la administracion en forma topica de una composicion farmaceutica que comprende 4-bromo-5-(2-imidazolin-2-ilamin)benzimidazol, en donde el ojo afectado tiene una presion intraocular inferior a la de la linea base; y articulo de elaboracion que comprende a dicha composicion.
CL2012002612A1 (es) Compuestos derivados de benciloxicicloalquiladenosina, como agonistas selectivos de receptores de adenosina a1; composicion farmaceutica oftalmica; y su uso para el tratamiento de una afeccion seleccionada entre presion intraocular elevada, hipertension ocular o glaucoma.
CO6660486A2 (es) Composición tópica famacéutica o cosmética útil para el tratamiento de enfermedades o condiciones que cursan con un déficit de la maduración de la envoltura córnea
UY31768A (es) Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre
EP4403220A3 (en) Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
MX2009003060A (es) Emulsion.
CL2012002613A1 (es) Metodo para reducir la presion intraocular que comprende suministrar un compuesto n6- ciclopentiladenosina a la camara anterior de un ojo afectado; compuestos derivados de n6- ciclopentiladenosina; composicion farmaceutica oftalmica que los comprende; y su uso para reducir la presion intraocular.

Legal Events

Date Code Title Description
FC Refusal